Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;43(5):1225-1228.
doi: 10.1111/ijlh.13492. Epub 2021 Feb 15.

Low prevalence of antiannexin A5 antibodies in unprovoked venous thrombosis

Wai Khoon Ho  1 , Joseph Rigano  1
Affiliations

Low prevalence of antiannexin A5 antibodies in unprovoked venous thrombosis

Wai Khoon Ho et al. Int J Lab Hematol. 2021 Oct.

Abstract

Introduction: The antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy morbidity, and the detection in the blood of at least one of three antiphospholipid antibodies (lupus anticoagulant, or anticardiolipin or anti-β2 -glycoprotein I antibodies). Diagnosing APS is important so that secondary prophylaxis may be administered to reduce risk of recurrent thrombosis and/or pregnancy morbidity. In addition to APS-defining antibodies, there may be additional autoantibodies that have a role in thrombosis and/or pregnancy morbidity. Furthermore, some patients have clinical manifestations highly suggestive of APS but are persistently negative for the APS-defining antibodies ("seronegative APS") and instead, have other autoantibodies. Antiannexin A5 (aANXA5) autoantibodies have been associated with increased risk of thrombosis and pregnancy morbidity; levels are also reportedly higher in patients with venous thrombosis compared with healthy controls. The prevalence of aANXA5 among patients with unprovoked venous thrombosis is not well-documented and determination of the frequency of aANXA5 is the objective of this study.

Methods: We analysed sera from 148 patients with unprovoked venous thrombosis who had undergone routine laboratory testing for the present APS-defining antibodies.

Results: aANXA5 IgG and IgM were present in 6% and 1%, respectively.

Conclusion: Prevalence of these antibodies in unprovoked venous thrombosis is comparable with frequencies reported in healthy individuals and is far lower than the prevalence in women with pregnancy morbidity. This may indicate lack of association with venous thrombosis, however, adequately powered case-control studies will be required to resolve this and prevalence data from this study will assist in the design of such studies.

Keywords: antiannexin A5 antibody; antiphospholipid antibodies; antiphospholipid syndrome; unprovoked venous thrombosis; “noncriteria” antibodies.

PubMed Disclaimer

References

REFERENCES

    1. Keeling D, Mackie I, Moore GW, Greer IA. Greaves M and British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157:47-58.
    1. Rodríguez-García V, Ioannou Y, Fernández-Nebro A, Isenberg DA, Giles IP. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology. 2015;54:2041-2050.
    1. Devreese KMJ, Ortel TL, Pengo V, de Laat B, for the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: Communication from the SSC of the ISTH. J Thromb Haemost. 2018;16:809-813.
    1. Božič B, Irman Š, Gašperšič N, Kveder T, Rozman B. Antibodies against annexin A5: detection pitfalls and clinical associations. Autoimmunity. 2005;38:426-430.
    1. Bertolaccini ML, Amengual O, Atsumi T, et al. ‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191-205.

MeSH terms

LinkOut - more resources